PLATELET AGGREGATION PLAYS a central role in the development of thrombus formation. Currently available antiplatelet agents, such as aspirin, show clinical efficacy in the treatment of arterial thrombotic disorders by inhibiting platelet aggregation (1, 2). However, because microthrombi produced in the early phase of platelet activation may be a trigger for additional development of larger thrombi, the inhibitory effect of these agents on the formation of microthrombi should be evaluated. Patients with diabetes have a few fold increases in the risk of dying of cardiovascular diseases (3, 4). Vascular stenosis due to thrombus formation is a major contributor, and it is generally accepted that platelets play an important role. Diabetic microvascular disease is a leading cause of coronary artery disease and renal failure, and these phenomena are major causes of blindness (5–7)
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.